Chicago Equity Partners LLC grew its position in shares of Merck & Company, Inc. (NYSE:MRK) by 5.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 483,000 shares of the company’s stock after acquiring an additional 24,045 shares during the quarter. Merck & Company, Inc. comprises about 0.8% of Chicago Equity Partners LLC’s investment portfolio, making the stock its 14th largest holding. Chicago Equity Partners LLC’s holdings in Merck & Company, Inc. were worth $30,955,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in MRK. Principal Financial Group Inc. boosted its holdings in shares of Merck & Company, Inc. by 40.4% during the second quarter. Principal Financial Group Inc. now owns 8,012,726 shares of the company’s stock valued at $513,535,000 after acquiring an additional 2,304,142 shares during the period. Canada Pension Plan Investment Board boosted its holdings in shares of Merck & Company, Inc. by 70.4% during the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after acquiring an additional 2,300,200 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Merck & Company, Inc. by 23.7% during the first quarter. AQR Capital Management LLC now owns 8,146,594 shares of the company’s stock valued at $517,635,000 after acquiring an additional 1,561,853 shares during the period. Karp Capital Management Corp acquired a new position in shares of Merck & Company, Inc. during the first quarter valued at $94,200,000. Finally, CIBC World Markets Inc. boosted its holdings in shares of Merck & Company, Inc. by 536.0% during the first quarter. CIBC World Markets Inc. now owns 1,290,373 shares of the company’s stock valued at $81,990,000 after acquiring an additional 1,087,497 shares during the period. 72.98% of the stock is owned by institutional investors.

Shares of Merck & Company, Inc. (NYSE MRK) opened at $54.35 on Friday. The firm has a market cap of $148,073.14, a PE ratio of 13.97, a P/E/G ratio of 2.34 and a beta of 0.78. Merck & Company, Inc. has a 1-year low of $53.63 and a 1-year high of $66.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.

Merck & Company, Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & Company, Inc. had a net margin of 11.60% and a return on equity of 27.08%. The firm had revenue of $10.33 billion for the quarter, compared to analysts’ expectations of $10.54 billion. During the same period in the previous year, the business earned $1.07 earnings per share. Merck & Company, Inc.’s revenue for the quarter was down 2.0% compared to the same quarter last year. analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

In other Merck & Company, Inc. news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.25% of the stock is currently owned by insiders.

Several equities analysts have recently issued reports on MRK shares. Cowen Inc reissued a “hold” rating and set a $70.00 price target on shares of Merck & Company, Inc. in a report on Friday, November 3rd. J P Morgan Chase & Co set a $70.00 price objective on shares of Merck & Company, Inc. and gave the stock a “buy” rating in a report on Sunday, October 29th. Zacks Investment Research downgraded shares of Merck & Company, Inc. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $55.00 price objective on shares of Merck & Company, Inc. in a report on Friday, October 20th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Merck & Company, Inc. in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. Merck & Company, Inc. currently has a consensus rating of “Hold” and a consensus target price of $66.44.

TRADEMARK VIOLATION NOTICE: “Chicago Equity Partners LLC Has $30.96 Million Stake in Merck & Company, Inc. (MRK)” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/chicago-equity-partners-llc-has-30-96-million-stake-in-merck-company-inc-mrk/1727478.html.

Merck & Company, Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.